- Home
- GSK vs REGN Comparison
GSK vs REGN Comparison
Compare GSK & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSK
- REGN
- Stock Information
- Founded
- GSK 1715
- REGN 1988
- Country
- GSK United Kingdom
- REGN United States
- Employees
- GSK N/A
- REGN N/A
- Industry
- GSK Biotechnology: Pharmaceutical Preparations
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- GSK Health Care
- REGN Health Care
- Exchange
- GSK Nasdaq
- REGN Nasdaq
- Market Cap
- GSK 78.9B
- REGN 63.4B
- IPO Year
- GSK N/A
- REGN 1991
- Fundamental
- Price
- GSK $41.40
- REGN $524.77
- Analyst Decision
- GSK Hold
- REGN Buy
- Analyst Count
- GSK 3
- REGN 23
- Target Price
- GSK N/A
- REGN $854.26
- AVG Volume (30 Days)
- GSK 4.5M
- REGN 1.5M
- Earning Date
- GSK 07-30-2025
- REGN 07-31-2025
- Dividend Yield
- GSK 3.78%
- REGN 0.34%
- EPS Growth
- GSK N/A
- REGN 16.49
- EPS
- GSK 0.98
- REGN 39.43
- Revenue
- GSK $40,735,668,430.00
- REGN $14,085,700,000.00
- Revenue This Year
- GSK $6.70
- REGN N/A
- Revenue Next Year
- GSK $5.42
- REGN $6.83
- P/E Ratio
- GSK $20.52
- REGN $13.24
- Revenue Growth
- GSK 2.57
- REGN 7.52
- 52 Week Low
- GSK $31.72
- REGN $476.49
- 52 Week High
- GSK $44.67
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- GSK 62.52
- REGN 42.60
- Support Level
- GSK $40.67
- REGN $512.97
- Resistance Level
- GSK $42.63
- REGN $529.99
- Average True Range (ATR)
- GSK 0.56
- REGN 16.72
- MACD
- GSK 0.12
- REGN 0.07
- Stochastic Oscillator
- GSK 73.88
- REGN 32.23
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).